Wyniki wyszukiwania

1

Expression of angiogenic factor with G patch and FHA domains 1 (AGGF1) in placenta from patients with preeclampsia

100%

An L.-F., Chi S. Q., Zhang J., Wang H.-B., Ouyang W.-X.

Folia Histochemica et Cytobiologica

|

2020

|

tom 58

|

nr 2

2

The hidden side of disodium cromolyn: from mast cell stabilizer to an angiogenic factor and antitumor agent

84%

Cimpean A. M., Raica M.

Archivum Immunologiae et Therapiae Experimentalis

|

2016

|

tom 64

|

nr 6

3

The effects of indomethacin on angiogenic factors mRNA expression in renal cortex of healthy rats

84%

Mucha K., Foroncewicz B., Koziak K., Czarkowska-Paczek B., Paczek L.

Journal of Physiology and Pharmacology

|

2007

|

tom 58

|

nr 1

Indomethacin is a nonsteroidal anti-inflammatory drug used frequently to control chronic or temporary pain. In the kidney, indomethacin decreases medullary and cortical perfusion, resulting in hypoxia. Kidney hypoxia has many effects, including changes in gene expression, and is a strong stimulus for angiogenesis. Other angiogenic factors include vascular endothelial growth factor (VEGF), basic fibroblast growth factor (FGF-2), transforming growth factor beta 1 (TGFß1), and platelet-derived growth factor (PDGF). Our goal was to examine the influence of indomethacin on mRNA expression of these factors and their selected receptors in the renal cortex of healthy rats. Groups of 8 healthy, male, six-week-old Wistar rats received either indomethacin (5 mg/kg/day) or placebo orally for three months. RNA from renal cortex biopsies was analyzed by real-time polymerase chain reaction to quantify the mRNA levels of each cytokine. We observed significantly higher mRNA levels for VEGF (1.73-fold), FGF-2 (5.6-fold) and TGFß receptor III (2.93-fold), PDGF receptor alpha (2.93-fold) and receptor ß (2.91-fold) in rats receiving indomethacin compared to rats given placebo (p < 0.05). Amounts of mRNA for TGFß1, PDGF, FGF receptors 1 and 2 and TGFß receptor I did not differ between analysed groups. Our data indicates that indomethacin may regulate the expression of potent angiogenic factors VEGF and FGF-2.

4

Blood specimen biomarkers of inflammation, matrix degradation, angiogenesis, and cardiac involvement: a future useful tool in assessing clinical outcomes of COPD patients in clinical practice?

67%

Kristan S. S.

Archivum Immunologiae et Therapiae Experimentalis

|

2013

|

tom 61

|

nr 6

5

Artykuł dostępny w postaci pełnego tekstu - kliknij by otworzyć plik

Therapeutic potential of heme oxygenase-1 in cardiovascular disease

59%

Jazwa A., Florczyk U., Stepniewski J., Jozkowicz A., Dulak J.

BioTechnologia. Journal of Biotechnology Computational Biology and Bionanotechnology

|

2011

|

tom 92

|

nr 2

Ograniczanie wyników

2 Archivum Immunologiae et Therapiae Experimentalis

1 BioTechnologia. Journal of Biotechnology Computational Biology and Bionanotechnology

1 Folia Histochemica et Cytobiologica

1 Journal of Physiology and Pharmacology

1 An L.-F.

1 Chi S. Q.

1 Cimpean A. M.

1 Czarkowska-Paczek B.

1 Dulak J.

1 Florczyk U.

1 Foroncewicz B.

1 Jazwa A.

1 Jozkowicz A.

1 Koziak K.

1 Kristan S. S.

1 Mucha K.

1 Ouyang W.-X.

1 Paczek L.

1 Raica M.

1 Stepniewski J.

1 Wang H.-B.

1 Zhang J.

1 2020

1 2016

1 2013

1 2011

1 2007

Expression of angiogenic factor with G patch and FHA domains 1 (AGGF1) in placenta from patients with preeclampsia

The hidden side of disodium cromolyn: from mast cell stabilizer to an angiogenic factor and antitumor agent

The effects of indomethacin on angiogenic factors mRNA expression in renal cortex of healthy rats

Blood specimen biomarkers of inflammation, matrix degradation, angiogenesis, and cardiac involvement: a future useful tool in assessing clinical outcomes of COPD patients in clinical practice?

Therapeutic potential of heme oxygenase-1 in cardiovascular disease